Astria Therapeutics, Inc.
NASDAQ: ATXS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jill C. Milne
- Employees
- 78
- Headquarters
- Boston, United States
- IPO year
- 2015
- Market cap
- $718.1M
- Website
- https://www.astriatx.com
Loading ATXS…
Loading profile data…Frequently asked questions about ATXS
What does Astria Therapeutics, Inc. (ATXS) do?
Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. The firm specializes in identifying, advancing, and bringing to market treatments for uncommon and specialized allergic and immunological disorders across the United States. Its leading experimental drug, STAR-0215, is a monoclonal antib...
Where does ATXS trade?
Astria Therapeutics, Inc. (ATXS) trades on the NASDAQ Global Market.
What sector is ATXS in?
Astria Therapeutics, Inc. (ATXS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Astria Therapeutics, Inc.?
Jill C. Milne is the chief executive officer of Astria Therapeutics, Inc. (ATXS).
Where is Astria Therapeutics, Inc. headquartered?
Astria Therapeutics, Inc. is headquartered in United States.
Does ATXS pay a dividend?
Astria Therapeutics, Inc. (ATXS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ATXS go public?
Astria Therapeutics, Inc. (ATXS) completed its initial public offering in 2015.